Results 101 to 110 of about 6,042 (221)

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Rheumatology and Therapy
Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with ...
Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman   +8 more
doaj   +1 more source

Paediatric psoriasis and biologics: An evidence gap in plain sight

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 556-557, April 2026.
Stephan Traidl, Sascha Gerdes
wiley   +1 more source

The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review

Experimental Dermatology, Volume 35, Issue 3, March 2026.
ABSTRACT The human gut microbiota is involved in immune regulation, metabolism, and skin homeostasis. In recent years, gut microbiota alterations have been linked with several inflammatory skin disorders, such as atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa (HS).
Andrea Malgesini, Matteo Domenico Marsiglia, Elisa Borghi, Angelo V. Marzano, Gianluca Nazzaro   +4 more
wiley   +1 more source

Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease [PDF]

Interleukin (IL) 23, a member of the IL12 family of cytokines, maintains intestinal homeostasis, but is also implicated in the pathogenesis of inflammatory bowel diseases (IBDs). The IL23 receptor is a heterodimer composed of disulfide-linked p19 and p23
Bourgonje, Arno R., Colombel, Jean-Frederic, Mehandru, Saurabh, Ungaro, Ryan C.   +3 more
core   +1 more source

Long‐term safety and efficacy in paediatric psoriasis: Remaining challenges

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 558-559, April 2026.
Catherine Droitcourt, Ninon Le Goaziou
wiley   +1 more source

Exonic Variation in HLA‐C, CFB, and TAP2 Associated With Increased Risk for Comorbid Crohn's Disease and Psoriasis

International Journal of Dermatology, Volume 65, Issue 3, Page 553-562, March 2026.
Our recent work established an association between high polygenic risk scores (PRSes) for both psoriasis and Crohn's disease with the development of comorbid disease. The protein‐coding genetic variation associated with the development of comorbid psoriasis and Crohn's disease is understudied.
Vikram R. Shaw, Jinyoung Byun, Catherine Zhu, Jared Sninsky, Younghun Han, Jeffrey M. Cohen, Christopher I. Amos   +6 more
wiley   +1 more source

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

ACR Open Rheumatology
Objective Group‐level analyses from the phase 3 DISCOVER‐2 trial of guselkumab demonstrated robust and durable improvements across psoriatic arthritis (PsA) domains.
Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes   +11 more
doaj   +1 more source

Guselkumab

Annales de Dermatologie et de Vénéréologie, 2019
  +6 more sources

Mild psoriasis as a suitable model for proof-of-mechanism in a phase 1B setting:Results from a double-blind placebo-controlled trial with guselkumab [PDF]

AimsEarly clinical development of novel psoriasis therapies is hampered by a decreasing number of moderate-to-severe psoriasis patients eligible for participation in trials since efficacious treatments, such as biologics, have become widely available ...
Bergmans, Menthe E., Bohoslavsky, Roman, Bouwstra, Joke A., Bruijnincx, Lisa J., Der Kolk, Tessa Niemeyer-van, Klarenbeek, Naomi B., Lin, Sissi, Rissmann, Robert, Rousel, Jannik, van Doorn, Martijn B. A., Yavuz, Yalcin   +10 more
core   +2 more sources

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison

Psoriasis: Targets and Therapy, 2021
Philip Hampton,1 Emma Borg,2 Jes Birger Hansen,2 Matthias Augustin3 1Department of Dermatology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; 2LEO Pharma A/S, Ballerup, Denmark; 3Institute for Health Services Research in ...
Hampton P, Borg E, Hansen JB, Augustin M
doaj